The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease

Table 4 The comparison of the characteristics of patients treated with furosemide, dapagliflozin and tolvaptan (at baseline/at day 7)

Characteristics	Furosemide	Dapagliflozin	Tolvaptan	p value
Number	16	36	13
Age (years)	70.1 ± 4.0	68.5 ± 2.1	72.9 ± 3.0	0.575
Male gender (%)	68.8	66.7	69.2	0.980
Body weight (kg) [baseline]	67.9 ± 3.0	69.0 ± 2.7	68.4 ± 4.9	0.988
BMI (kg/m²) [baseline]	26.0 ± 0.9	27.1 ± 0.8	27.3 ± 1.3	0.657
Diabetes kidney disease (%)	50.0	100	46.2	< 0.001
Systolic BP (mmHg) [baseline]	133 ± 7	138 ± 4	131 ± 5	0.621
Serum albumin (g/dL) [baseline]	1.9 (1.5–2.7)	3.5 (2.8–4.0)	2.7 (2.1–3.4)	< 0.001
eGFR (mL/min/1.73 m²) [baseline]	33.3 (13.3–60.3)	27.8 (19.2–42.0)	13.2 (9.4–21.5)	0.007
ECW/TBW [baseline]	0.431 ± 0.004	0.415 ± 0.004	0.419 ± 0.005	0.028
[day 7]	0.416 ± 0.004	0.409 ± 0.003	0.417 ± 0.005	0.224
Absolute change in ECW/TBW^a	− 0.015 ± 0.002	− 0.005 ± 0.001	− 0.002 ± 0.002	0.001
Diuretics (%)	100	66.7	100	< 0.001

BMI body mass index, BP blood pressure, eGFR estimated glomerular filtration rate, ICW intracellular water, ECW extracellular water, TBW: total body water
^aDay 7 vs. baseline. Values are presented as the mean ± standard error or as median (interquartile range)

ISSN: 1758-5996